Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

PARP inhibitors have been proven clinically efficacious in platinum-responsive ovarian cancer regardless of BRCA1/2 status and in breast cancers with germline BRCA1/2 mutation. However, resistance to PARP inhibitors may preexist or evolve during treatment in many cancer types and may be overcome by...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zebin, Sun, Kaiming, Xiao, Yonghong, Feng, Bin, Mikule, Keith, Ma, XiaoYan, Feng, Ningping, Vellano, Christopher P., Federico, Lorenzo, Marszalek, Joseph R., Mills, Gordon B., Hanke, Jeffrey, Ramaswamy, Sridhar, Wang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372650/
https://www.ncbi.nlm.nih.gov/pubmed/30755715
http://dx.doi.org/10.1038/s41598-019-38534-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372650/
https://www.ncbi.nlm.nih.gov/pubmed/30755715
http://dx.doi.org/10.1038/s41598-019-38534-6

Ejemplares similares